EA202192635A1 - Фармацевтическая композиция, содержащая бензоазепиновое соединение - Google Patents

Фармацевтическая композиция, содержащая бензоазепиновое соединение

Info

Publication number
EA202192635A1
EA202192635A1 EA202192635A EA202192635A EA202192635A1 EA 202192635 A1 EA202192635 A1 EA 202192635A1 EA 202192635 A EA202192635 A EA 202192635A EA 202192635 A EA202192635 A EA 202192635A EA 202192635 A1 EA202192635 A1 EA 202192635A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
composition containing
benzoazepine compound
agent
formula
Prior art date
Application number
EA202192635A
Other languages
English (en)
Inventor
Томихико Тихара
Синго Уно
Original Assignee
Оцука Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оцука Фармасьютикал Ко., Лтд. filed Critical Оцука Фармасьютикал Ко., Лтд.
Publication of EA202192635A1 publication Critical patent/EA202192635A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Представлено средство для уменьшения побочных эффектов толваптана. В частности, средство представляет собой фармацевтическую композицию, включающую соединение, представленное формулой (1)или его соль металла, при этом фармацевтическую композицию используют таким образом, что соединение, представленное формулой (1), или его соль металла вводят трансваскулярно в количестве 4-20 мг в течение периода времени 10 мин или больше.
EA202192635A 2019-03-28 2020-03-27 Фармацевтическая композиция, содержащая бензоазепиновое соединение EA202192635A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019064357 2019-03-28
PCT/JP2020/013935 WO2020196816A1 (en) 2019-03-28 2020-03-27 Benzoazepine compound-containing pharmaceutical composition

Publications (1)

Publication Number Publication Date
EA202192635A1 true EA202192635A1 (ru) 2021-12-10

Family

ID=70289832

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192635A EA202192635A1 (ru) 2019-03-28 2020-03-27 Фармацевтическая композиция, содержащая бензоазепиновое соединение

Country Status (7)

Country Link
US (1) US20220152064A1 (ru)
EP (1) EP3946362A1 (ru)
JP (2) JP7130879B2 (ru)
KR (1) KR20210144811A (ru)
CN (1) CN113631169A (ru)
EA (1) EA202192635A1 (ru)
WO (1) WO2020196816A1 (ru)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100004206A1 (en) * 2005-12-27 2010-01-07 Makoto Komatsu Water-soluble benzoazepine compound and its pharmaceutical composition
JP5590780B2 (ja) * 2007-06-26 2014-09-17 大塚製薬株式会社 医薬
TW201605488A (zh) * 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物

Also Published As

Publication number Publication date
WO2020196816A1 (en) 2020-10-01
KR20210144811A (ko) 2021-11-30
CN113631169A (zh) 2021-11-09
JP2022519343A (ja) 2022-03-23
US20220152064A1 (en) 2022-05-19
JP7130879B2 (ja) 2022-09-05
JP2022163190A (ja) 2022-10-25
EP3946362A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2020011196A (es) Una sal sodica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamo il)-1-isopropil-1h-pirazol-3-sulfonamida.
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MX2022001784A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos.
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
TW200639159A (en) Treatment of pain
MY145569A (en) Benzamide compounds useful as histone deacetylase inhibitors
TW200517106A (en) Sustained release pharmaceutical compositions
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
WO2012168885A9 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
PH12021550554A1 (en) N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors
MX2021014680A (es) Derivado de benzotriazol.
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MX2022006104A (es) Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma.
TW200719903A (en) Compositions for the treatment of neoplasms
MX2022008487A (es) Degradadores de smarca2-vhl.
JOP20190278A1 (ar) مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
PH12020551117A1 (en) Compositions for preventing or treating uveitis
EA202192635A1 (ru) Фармацевтическая композиция, содержащая бензоазепиновое соединение
MX2021008071A (es) Derivados de imidazol fusionado sustituido y métodos de tratamiento de la anemia de células falciformes y complicaciones relacionadas.